• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rare Non-Mucinous Enteric-Type Thymic Adenocarcinoma Case Reveals Pathogenic TP53 Mutation

by
November 13, 2026
in Health
Reading Time: 6 mins read
0
Rare Non-Mucinous Enteric-Type Thymic Adenocarcinoma Case Reveals Pathogenic TP53 Mutation

Rare Non-Mucinous Enteric-Type Thymic Adenocarcinoma Case Reveals Pathogenic TP53 Mutation

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A multidisciplinary surgical and pathology team reported the detailed clinical course, histopathology, and genomic findings of a 54-year-old woman diagnosed with an extremely rare non-mucinous enteric-type thymic adenocarcinoma harboring a pathogenic TP53 stop-gain mutation. The patient, who had no history of smoking or previous malignancies, was admitted following an abnormal shadow detected on routine chest radiography. Diagnostic workup showed a markedly elevated blood carcinoembryonic antigen level of 127 ng/mL against a normal threshold of less than 5 ng/mL, whereas other serum markers, including alpha-fetoprotein, beta-human chorionic gonadotropin, soluble interleukin-2 receptor, cytokeratin 19 fragment, and squamous cell carcinoma antigen, remained within normal limits.

Preoperative diagnostic imaging localized the lesion to the anterior mediastinum as a 5.5-centimeter mass with direct invasion into the right upper lung lobe. Fluorodeoxyglucose-positron emission tomography demonstrated intense metabolic accumulation restricted entirely to the mediastinal mass, reaching a maximal standardized uptake value of 11.51 with no evidence of distant metastasis or secondary primary tumors elsewhere in the body. Magnetic resonance imaging demonstrated tumor contact along the left brachiocephalic vein with a largely preserved fat plane and no definitive radiologic signs of direct luminal or vascular wall invasion, leading clinicians to suspect a resectable Masaoka stage III thymic epithelial malignancy prior to operative intervention.

Surgical exploration commenced with a three-port thoracoscopic approach through the right hemithorax, which immediately confirmed extensive tumor invasion into the right lung parenchyma and the pericardium. The surgical team converted the procedure to a median sternotomy to secure complete macroscopic oncologic clearance, performing an en bloc resection of the mediastinal tumor along with the involved right lung tissue, pericardial segments, and the left brachiocephalic vein, followed by pericardial reconstruction using a Gore-Tex patch. The team also sampled prevascular lymph node station 3a according to the International Association for the Study of Lung Cancer map; total operative time reached 228 minutes with 131 mL of blood loss, and the patient experienced an uneventful postoperative recovery, discharging on postoperative day six.

Macroscopic pathological evaluation revealed a 5.5-centimeter solid, poorly circumscribed mass with a cut surface that was partly white and yellowish-white with central necrotic foci. Microscopic examination demonstrated tall columnar tumor cells featuring enlarged nuclei that infiltrated surrounding tissue and formed irregular glandular lumina surrounded by severe fibrosis and vascular invasion, accompanied by direct infiltration into adjacent anterior mediastinal lymph nodes. Microscopic thymic cysts were identified along the periphery of the lesion, and histological evaluation confirmed the complete absence of mucin production, squamous cell differentiation, or papillary architecture.

Immunohistochemical profiling confirmed enteric differentiation, displaying positive staining for cytokeratin 7, partial positivity for cytokeratin 20, and nuclear positivity for caudal type homeobox 2 in approximately 50 percent of the neoplastic cells. Staining was entirely negative for thyroid transcription factor 1, p40, cluster of differentiation 5, KIT, and mucin-2. Because primary thymic adenocarcinoma accounts for only 1.6 percent of all thymic carcinomas and approximately 14 percent of thymic tumors overall, ruling out metastatic gastrointestinal adenocarcinoma was critical; the strong positivity for cytokeratin 7, which is typically absent in colorectal adenocarcinomas, combined with negative systemic PET-CT findings, established the primary thymic origin under the fifth edition of the World Health Organization classification.

Final staging classified the resected neoplasm as Masaoka stage IVB and TNM stage IVA (T3N1M0) based on confirmed direct extension to the brachiocephalic vein, pericardium, lung parenchyma, and regional lymph nodes. Because of the risk of microscopic residual disease, the patient received postoperative adjuvant radiation therapy consisting of 54 Gray delivered across 27 fractions. Following surgery and radiotherapy, circulating carcinoembryonic antigen concentrations dropped to normal physiological levels, and continuous clinical surveillance confirmed that the patient remained alive and in complete remission without local recurrence or distant metastasis four years postoperatively.

Targeted next-generation sequencing performed on the resected tumor using the 91-gene Axen Cancer Panel 1 achieved a total read depth of 3,821-fold and a mean read depth of 1,232-fold, covering 99.8 percent of targeted bases at 100-fold or higher. Sequence analysis identified a heterozygous TP53 stop-gain mutation, designated c.637C>T (p.Arg213*), at an allele frequency of 19.7 percent. This truncating alteration causes a direct loss of normal p53 tumor suppressor protein function and was classified as a clinically pathogenic molecular driver in the specimen.

The comprehensive panel also captured several non-synonymous single-nucleotide variants and small indels across other examined loci, including ERBB3 (c.3380G>A, p.Arg1127His) at 51.3 percent allele frequency, ERBB2 (c.428G>A, p.Arg143Gln) at 41.3 percent, FGFR1 (c.304G>A, p.Val102Ile) at 43.4 percent, MLH1 (c.1744C>G, p.Leu582Val) at 51.2 percent, and BRCA2 (c.7378A>C, p.Asn2460His) at 0.9 percent. An in-frame duplication was also identified in AR (c.234_239dupGCA, p.Gln79_Gln80dup) at an allele frequency of 100 percent, whereas no actionable structural gene fusions or copy number alterations were observed.

A review of published medical literature indicated that only 35 cases of enteric-type thymic adenocarcinoma have been documented to date, among which only 11, including this patient, represented the non-mucinous subtype. In that 11-case cohort, patient ages averaged 51 years across six men and five women, presenting across Masaoka stages I through IVB. Prior genetic reports in enteric-type thymic malignancies were confined to three mucinous cases detailing alterations in KRAS, STK11/LKB1, or TP53 with MYC amplification, making this the first genetic profiling report characterizing the non-mucinous enteric subtype.

The authors emphasized that routine magnetic resonance imaging may underestimate subtle adventitial venous invasion, as histopathology confirmed vascular wall infiltration despite preserved preoperative fat planes, suggesting that high fluorodeoxyglucose avidity should prompt heightened suspicion during operative planning. Although published survival benchmarks vary widely across adenocarcinoma subtypes—with median survival reported at 85.6 months for enteric-type versus 22.1 months for non-enteric variants in one comparative study—the authors noted that broader international genomic registries are needed to clarify how TP53 mutations and related molecular alterations influence prognosis in these rare thoracic malignancies.

The diagnostic framework for this malignancy aligns with structural revisions introduced in the fifth edition of the World Health Organization classification of thoracic tumors. Under this updated system, thymic adenocarcinomas are divided into four distinct histological groups: low-grade papillary adenocarcinoma, thymic carcinoma with adenoid cystic carcinoma-like features, enteric-type adenocarcinoma, and adenocarcinoma not otherwise specified. To formally establish an enteric-type designation, diagnostic criteria require the tumor to exhibit positive immunohistochemical expression for at least one of three classical intestinal lineage markers: caudal type homeobox 2, cytokeratin 20, or mucin-2. Furthermore, these neoplasms typically show no immunoreactivity for thyroid transcription factor 1 or c-KIT, while cytokeratin 7 and cluster of differentiation 5 may yield variable positive or negative staining patterns. Morphologically, these tumors exhibit colorectal features, characterized by tall columnar epithelial cells that proliferate in papillary tubular arrangements while organizing into neoplastic nests.

The identification of the stop-gain alteration also provides insight into the genomic context of thymic malignancies. Across the broader spectrum of thymic carcinomas, including squamous cell carcinoma, TP53 mutations represent frequent somatic alterations occurring in approximately 7 to 25 percent of cases. Hotspot mutations within TP53 are regarded as key alterations responsible for tumor development and progression. Truncating alterations like the p.Arg213* variant eliminate tumor suppressor function, and studies in thymic carcinoma have consistently linked TP53 abnormalities to increased malignancy, higher recurrence rates, and poorer survival outcomes. These alterations contrast with other recognized molecular abnormalities in thymic carcinoma, such as CDKN2A inactivation detected in up to 40 percent of cases, CDKN2B inactivation documented in up to 25 percent, and KIT mutations observed in 6 to 12 percent of tumors.

Another notable histopathological feature documented in the report was the presence of microscopic thymic cysts along the borders of the lesion. According to the research team, more than half of all reported cases of enteric-type thymic adenocarcinoma present with adjacent thymic cysts. Two distinct biological mechanisms have been proposed to explain this recurring association. The first hypothesis suggests that preexisting cyst epithelium undergoes direct malignant transformation into invasive adenocarcinoma. The second model proposes that cystic formation represents a secondary reactive process, occurring when normal thymic epithelium proliferates in response to exposure to tumor antigens.

The cohort analysis of the 11 known non-mucinous enteric-type cases provides further perspective on clinical presentation and management patterns. When categorized by Masaoka clinical staging, two patients presented with stage I disease, three with stage II, two with stage III, and four with advanced stage IVb disease. Biomarker profiles across this small group revealed variable expression: serum carcinoembryonic antigen levels were elevated in three patients, whereas five patients demonstrated normal baseline concentrations, showing that normal marker values do not exclude the diagnosis. Therapeutic approaches centered predominantly on operative intervention, with surgical resection carried out in eight of the eleven patients, supplemented by radiotherapy, chemotherapy, or both depending on individual clinical staging.

Finally, the researchers emphasized that the targeted next-generation sequencing protocol required non-synonymous variants and small indels to achieve an allele frequency of at least 2 percent alongside a read depth of at least 100-fold for clinical interpretation. Because reports on the genetic characteristics of enteric-type thymic adenocarcinoma are limited, further accumulation of genetic and clinical data is essential.

Subject of Research: Genomic profiling and surgical management of non-mucinous enteric-type thymic adenocarcinoma

Article Title: Non-mucinous, enteric-type thymic adenocarcinoma: genetic analysis of a case

Article References: Narusawa, E., Ohtaki, Y., Ishii, G., Nakazawa, S., Kawatani, N., Yazawa, T., Numajiri, K., Yoshida, Y., Nimura, K., & Shirabe, K. (2026). Non-mucinous, enteric-type thymic adenocarcinoma: genetic analysis of a case. General Thoracic and Cardiovascular Surgery Cases, 5(1), Article 8. https://doi.org/10.1186/s44215-026-00240-x

Image Credits: AI Generated

DOI: 10.1186/s44215-026-00240-x

Keywords: thymic adenocarcinoma, thymic carcinoma, enteric-type thymic adenocarcinoma, non-mucinous thymic adenocarcinoma, TP53 mutation, carcinoembryonic antigen, anterior mediastinum, median sternotomy, cytokeratin 20, caudal type homeobox 2, next generation sequencing, Masaoka staging, adjuvant radiation therapy, brachiocephalic vein invasion, thymic cysts, Axen Cancer Panel 1, thoracic oncology

News Source: Nathaniel Bowman. (November 13, 2026). Rare Non-Mucinous Enteric-Type Thymic Adenocarcinoma Case Reveals Pathogenic TP53 Mutation. Scienmag.

Tags: adjuvant radiation therapyAnterior MediastinumAxen Cancer Panel 1brachiocephalic vein invasionCarcinoembryonic Antigencaudal type homeobox 2cytokeratin 20enteric-type thymic adenocarcinomaMasaoka stagingmedian sternotomynext-generation sequencingnon-mucinous thymic adenocarcinomathoracic oncologythymic adenocarcinomathymic carcinomathymic cystsTP53 mutation
Share12Tweet7Share2ShareShareShare1

Related Posts

Curved M1 Segment Linked to Higher Temporary Clipping Odds in Aneurysm Surgery

Curved M1 Segment Linked to Higher Temporary Clipping Odds in Aneurysm Surgery

November 19, 2026
Survey Links AI Training and Professional Title to Anesthesia Nurse AI Literacy

Survey Links AI Training and Professional Title to Anesthesia Nurse AI Literacy

November 19, 2026

Pediatric Cerebral Visual Impairment Shows Widespread Brain Changes on High-Field MRI

November 19, 2026

Rwandan Health Workers Demonstrate Moderate Infection Control Knowledge in Preparedness Study

November 19, 2026

POPULAR NEWS

  • Neuropathic Pain Affects Over Forty Percent of Patients With Rare CANVAS Disorder

    Neuropathic Pain Affects Over Forty Percent of Patients With Rare CANVAS Disorder

    29 shares
    Share 12 Tweet 7
  • Novel Phenylthiazolylquinoline Derivatives Show Potent In Vitro Cancer Cell Growth Inhibition

    29 shares
    Share 12 Tweet 7
  • Review Examines Central Nervous System Risks From Low-Frequency Sound and Infrasound

    29 shares
    Share 12 Tweet 7
  • Surgery Fails to Outperform Conservative Care for Pain in Fibrous Dysplasia

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Curved M1 Segment Linked to Higher Temporary Clipping Odds in Aneurysm Surgery

Ultrafast 4D Ultrasound Angiography Maps Deep Primate Cerebral Blood Flow Through Intact Skulls

Survey Links AI Training and Professional Title to Anesthesia Nurse AI Literacy

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.